Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases, announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behcet's disease. This milestone is expected to lead to orphan drug designation by the European Commission, providing incentives including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity upon approval.
Behcet's disease is a rare, chronic inflammatory disorder affecting blood vessels throughout the body, causing mouth and genital sores, skin lesions, and eye inflammation. There is currently no cure, and treatment options are limited. Dusquetide is an innate defense regulator (IDR), a novel class of compounds that modulate the body's innate immune system rather than suppressing it, offering a potential new approach for patients with unmet medical needs.
Dr. Christopher J. Schaber, CEO and president of Soligenix, expressed enthusiasm: 'We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program.' This designation not only validates the scientific rationale behind dusquetide but also provides significant development advantages that could accelerate its path to patients.
The positive EMA opinion marks a critical step forward for the SGX945 program, which is part of Soligenix's broader pipeline targeting rare inflammatory diseases. The company's focus on areas of high unmet need underscores the potential impact of this therapy. For patients living with rare diseases, regulatory milestones often determine whether research progresses or stalls. This announcement signals meaningful progress for the dusquetide development program.
Soligenix continues to advance its clinical programs, with the orphan drug designation expected to facilitate further development and potentially bring a new treatment option to patients suffering from Behcet's disease. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
